STOCK TITAN

Glaukos COO Gilliam exercises options, sells 44,917 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Glaukos Corp (GKOS) President & COO Joseph E. Gilliam exercised options for 44,917 common shares on November 12, 2026. The five reported option lots were 2,475 shares at $69.30, 7,500 shares in each of two lots at $48.46, and 11,250 and 16,192 shares at $55.18 per share.

Gilliam also sold 44,917 shares in six transactions that day; reported weighted-average sale prices ranged from $243.41 to $248.42 per share. The option exercises and sales were effected pursuant to a Rule 10b5-1 trading plan.

Insider Gilliam Joseph E
Role PRESIDENT & COO
Sold 44,917 shs ($11.06M)
Approx. gross sale proceeds $11.06M
Approx. exercise cost $2.41M
Approx. pre-tax spread $8.65M
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F9, F10 2,475 $0.00 $0.00
Exercise Stock Option (Right to Buy) F9, F10 7,500 $0.00 $0.00
Exercise Stock Option (Right to Buy) F9, F11 7,500 $0.00 $0.00
Exercise Stock Option (Right to Buy) F9, F12 11,250 $0.00 $0.00
Exercise Stock Option (Right to Buy) F9, F13 16,192 $0.00 $0.00
Exercise Common Stock F1 2,475 $69.30 $172K
Exercise Common Stock F1 7,500 $48.46 $363K
Exercise Common Stock F1 11,250 $55.18 $621K
Exercise Common Stock F1 16,192 $55.18 $893K
Exercise Common Stock F1 7,500 $48.46 $363K
Sale Common Stock F2, F3, F1 2,402 $243.41 $585K
Sale Common Stock F2, F4, F1 3,700 $244.49 $905K
Sale Common Stock F2, F5, F1 8,015 $245.77 $1.97M
Sale Common Stock F2, F6, F1 18,440 $246.49 $4.55M
Sale Common Stock F2, F7, F1 12,060 $247.50 $2.98M
Sale Common Stock F2, F8, F1 300 $248.42 $75K
Holdings After Transaction: Stock Option (Right to Buy) — 94,073 options (Direct); Common Stock — 71,602 shares (Direct)
Footnotes (13)
  1. F1. Includes 40,039 restricted stock units that have not yet vested or been delivered to the Reporting Person.
  2. F2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2026.
  3. F3. This transaction was executed in multiple trades at prices ranging from $242.96 to $243.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. F4. This transaction was executed in multiple trades at prices ranging from $244.00 to $245.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  5. F5. This transaction was executed in multiple trades at prices ranging from $245.06 to $246.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  6. F6. This transaction was executed in multiple trades at prices ranging from $246.07 to $247.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  7. F7. This transaction was executed in multiple trades at prices ranging from $247.08 to $248.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  8. F8. This transaction was executed in multiple trades at prices ranging from $248.34 to $248.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  9. F9. The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2026.
  10. F10. These options vest over four years from the grant date, with 25% vesting on the first anniversary of the grant date and the remaining amount vesting in equal monthly installments over the following three years.
  11. F11. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer on March 22, 2023, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period.
  12. F12. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer to the Reporting Person on March 24, 2022 in connection with his promotion to President and Chief Operating Officer, the vesting of which was subject to the Issuer's achievement of certain multi-year performance goals.
  13. F13. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer on March 24, 2022, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period.
Shares acquired through option exercises 44,917 shares November 12, 2026
Shares sold 44,917 shares Six transactions on November 12, 2026
Option exercise prices $48.46, $55.18, and $69.30 per share Reported option lots exercised on November 12, 2026
Weighted-average sale prices $243.41 to $248.42 per share Six sale transactions on November 12, 2026
Rule 10b5-1 trading plan regulatory
"sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"the price reported above reflects the weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
restricted stock units financial
"Includes 40,039 restricted stock units that have not yet vested or been delivered"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many GKOS shares did Joseph E. Gilliam sell, and at what prices?

Joseph E. Gilliam sold 44,917 shares on November 12, 2026, in six transactions. The reported weighted-average prices ranged from $243.41 to $248.42 per share; footnotes say each sale involved multiple trades.

Were the GKOS option exercises and sales made under a trading plan?

Yes. The option exercises and sales were effected pursuant to a Rule 10b5-1 trading plan Gilliam adopted on August 13, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gilliam Joseph E

(Last)(First)(Middle)
C/O GLAUKOS CORPORATION
ONE GLAUKOS WAY

(Street)
ALISO VIEJO CALIFORNIA 92656

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
GLAUKOS Corp [ GKOS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
PRESIDENT & COO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/12/2026M2,475A$69.374,077(1)D
Common Stock11/12/2026M7,500A$48.4681,577(1)D
Common Stock11/12/2026M11,250A$55.1892,827(1)D
Common Stock11/12/2026M16,192A$55.18109,019(1)D
Common Stock11/12/2026M7,500A$48.46116,519(1)D
Common Stock11/12/2026S(2)2,402D$243.41(3)114,117(1)D
Common Stock11/12/2026S(2)3,700D$244.49(4)110,417(1)D
Common Stock11/12/2026S(2)8,015D$245.77(5)102,402(1)D
Common Stock11/12/2026S(2)18,440D$246.49(6)83,962(1)D
Common Stock11/12/2026S(2)12,060D$247.5(7)71,902(1)D
Common Stock11/12/2026S(2)300D$248.42(8)71,602(1)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$69.311/12/2026M2,475(9) (10)03/14/2029Common Stock2,475$0825D
Stock Option (Right to Buy)$48.4611/12/2026M7,500(9) (10)03/22/2033Common Stock7,500$019,251D
Stock Option (Right to Buy)$48.4611/12/2026M7,500(9) (11)03/22/2033Common Stock7,500$019,251D
Stock Option (Right to Buy)$55.1811/12/2026M11,250(9) (12)03/24/2032Common Stock11,250$019,463D
Stock Option (Right to Buy)$55.1811/12/2026M16,192(9) (13)03/24/2032Common Stock16,192$035,283D
Explanation of Responses:
1. Includes 40,039 restricted stock units that have not yet vested or been delivered to the Reporting Person.
2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2026.
3. This transaction was executed in multiple trades at prices ranging from $242.96 to $243.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
4. This transaction was executed in multiple trades at prices ranging from $244.00 to $245.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
5. This transaction was executed in multiple trades at prices ranging from $245.06 to $246.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
6. This transaction was executed in multiple trades at prices ranging from $246.07 to $247.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
7. This transaction was executed in multiple trades at prices ranging from $247.08 to $248.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
8. This transaction was executed in multiple trades at prices ranging from $248.34 to $248.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
9. The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2026.
10. These options vest over four years from the grant date, with 25% vesting on the first anniversary of the grant date and the remaining amount vesting in equal monthly installments over the following three years.
11. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer on March 22, 2023, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period.
12. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer to the Reporting Person on March 24, 2022 in connection with his promotion to President and Chief Operating Officer, the vesting of which was subject to the Issuer's achievement of certain multi-year performance goals.
13. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer on March 24, 2022, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period.
Diana Scherer, Attorney-in-Fact11/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading